These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 32924107

  • 1. [Detection of del(17p13) among newly diagnosed multiple myeloma cases using cytoplasmic light chain immunofluorescence combined with FISH and its clinical significance].
    Lu X, Chen L, Shi Q, Qiu H, Li J, Guo R.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Oct 10; 37(10):1087-1091. PubMed ID: 32924107
    [Abstract] [Full Text] [Related]

  • 2. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H, Meng H, Wang J, Lou Y, Zhou Y, Lin P, Li F, Liu L, Xu H, Yang M, Jin J.
    Front Med; 2020 Jun 10; 14(3):327-334. PubMed ID: 31784918
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
    Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H.
    Blood; 2012 Jan 26; 119(4):940-8. PubMed ID: 22160383
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A.
    Hematol Oncol; 2013 Mar 26; 31(1):41-8. PubMed ID: 22674819
    [Abstract] [Full Text] [Related]

  • 7. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J.
    Am J Hematol; 2016 Nov 26; 91(11):E473-E477. PubMed ID: 27508939
    [Abstract] [Full Text] [Related]

  • 8. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y, Ke XY, Wang J, Wang YF, Dong F, Tian L, Wan W, Jing HM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun 26; 25(3):802-806. PubMed ID: 28641639
    [Abstract] [Full Text] [Related]

  • 9. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
    Königsberg R, Zojer N, Ackermann J, Krömer E, Kittler H, Fritz E, Kaufmann H, Nösslinger T, Riedl L, Gisslinger H, Jäger U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J.
    J Clin Oncol; 2000 Feb 26; 18(4):804-12. PubMed ID: 10673522
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
    Qiu Q, Zhu P, Wang MJ, Lu XZ, Dong YJ, Sun YH, Wang LH, Zhang Y, Bu DF, Wang WS, Liang ZY, Liu W, Qiu ZX, Ou JP, Cen XN.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug 26; 24(4):1071-8. PubMed ID: 27531777
    [Abstract] [Full Text] [Related]

  • 12. [The prognostic impact of 1p21 deletion on newly diagnosed multiple myeloma patients receiving thalidomide-based first-line treatment].
    Li F, Xu Y, An G, Hu LP, Zhang YR, Li ZJ, Yuan WP, Cheng T, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Oct 26; 34(10):862-7. PubMed ID: 24171960
    [Abstract] [Full Text] [Related]

  • 13. Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.
    Li C, Chen L, Gao X, Qu X, Shen W, Yang R, Zhang R, Qiu H, Xu J, Lu H, Li J.
    Leuk Lymphoma; 2011 Feb 26; 52(2):260-4. PubMed ID: 21133734
    [Abstract] [Full Text] [Related]

  • 14. [Application of fluorescence in-situ hybridization technique in multiple myeloma].
    Zhao Y, Zheng D, Li J, Zhu WT.
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep 26; 38(5):459-64. PubMed ID: 19830857
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
    Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón JA, Gutierrez NC, Bethge W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Penas EM, Dierlamm J, Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Nagler A, Kröger N.
    Leukemia; 2008 Jun 26; 22(6):1250-5. PubMed ID: 18418408
    [Abstract] [Full Text] [Related]

  • 17. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma].
    Liu SY, Huang JW, Zhang J, Du HP, Jiang H, Li JY, Xue YQ.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec 26; 24(6):685-8. PubMed ID: 18067084
    [Abstract] [Full Text] [Related]

  • 18. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F, Xu Y, Deng P, Yang Y, Sui W, Jin F, Hao M, Li Z, Zang M, Zhou D, Gu Z, Ru K, Wang J, Cheng T, Qiu L.
    Oncotarget; 2015 Apr 20; 6(11):9434-44. PubMed ID: 25831238
    [Abstract] [Full Text] [Related]

  • 19. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D.
    J Clin Oncol; 2013 Dec 01; 31(34):4325-32. PubMed ID: 24145347
    [Abstract] [Full Text] [Related]

  • 20. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH, Qi CX, Saha MN, Chang H.
    Am J Clin Pathol; 2012 Feb 01; 137(2):208-12. PubMed ID: 22261445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.